HIFU for Focal Ablation of Prostate Tissue: An Observational Study
NCT: NCT03620786 · RECRUITING
Publicidade
Resumo breve
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.
Fonte oficial
Ver no ClinicalTrials.gov →Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.